Jump to content

Peter Openshaw (immunologist): Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m added category
No edit summary
 
(14 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{short description|British physician and immunologist}}
{{short description|British physician and immunologist}}
{{Use dmy dates|date=April 2022}}
{{Infobox scientist
{{Infobox scientist
|name = Peter Openshaw
| name = Peter Openshaw
|honorific_suffix = {{post-nominals|country=GBR|size=100%|sep=,|CBE|FRCP|FMedSci}}
| honorific_suffix = {{post-nominals|country=GBR|size=100%|sep=,|CBE|FRCP|FMedSci}}
|birth_date = {{birth date and age|1954|11|11|df=y}}
| birth_date = {{birth date and age|1954|11|11|df=y}}
|birth_place = [[Glastonbury, Somerset]], England
| birth_place = [[Glastonbury, Somerset]], England
|fields = [[immunology]]
| fields = [[Immunology]]
|workplaces = [[Imperial College London]]
| workplaces = [[Imperial College London]]
|alma_mater = [[Guy's Hospital]]
| alma_mater = [[Guy's Hospital]]
| thesis_title = Benefit and harm from immunity to respiratory syncytial virus
| thesis_title = Benefit and harm from immunity to respiratory syncytial virus
| thesis_url = https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.238236
| thesis_url = https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.238236
| thesis_year = 1988
| thesis_year = 1988
| spouse = {{Marriage|[[Evelyn Welch]]}}
}}
}}
'''Peter John Morland Openshaw''', {{post-nominals|country=GBR|size=100%|sep=,|CBE|FRCP|FMedSci}} (born 11 November 1954) is a British clinician and scientist specialising in lung immunology, particularly defence against viral infections. He trained in lung diseases and undertook a PhD in immunology before establishing a laboratory at [[St Mary's Hospital Medical School]] (later part of [[Imperial College London]]). He created the academic department of Respiratory Medicine and the Centre for Respiratory Infection at Imperial College and was elected President of the [[British Society for Immunology]] in 2014.
'''Peter John Morland Openshaw''', {{post-nominals|country=GBR|size=100%|sep=,|CBE|FRCP|FMedSci}} (born 11 November 1954) is a British clinician and scientist specialising in lung [[immunology]], particularly defence against viral infections. He trained in lung diseases and undertook a PhD in immunology before establishing a laboratory at [[St Mary's Hospital Medical School]] (later part of [[Imperial College London]]). He created the academic department of Respiratory Medicine and the Centre for Respiratory Infection at Imperial College and was elected President of the [[British Society for Immunology]] in 2014.


==Early life==
==Early life==
Openshaw was born in 1954 in [[Glastonbury, Somerset]]. He attended Millfield Junior School, then the [[Quaker]] boarding schools [[Sidcot School]] and [[Bootham School]], followed by [[Guy's Hospital Medical School]] (University of London). He earned an intercalated BSc in Physiology (Hons., 1976), qualified in medicine (MB BS, 1979), and worked at the [[Royal Brompton Hospital]] and as medical registrar at [[Royal Postgraduate Medical School]] (Hammersmith Hospital).
Openshaw was born in 1954 in [[Glastonbury, Somerset]]. He attended [[Millfield]] Junior School, then the [[Quaker]] boarding schools [[Sidcot School]] and [[Bootham School]], followed by [[Guy's Hospital Medical School]] (University of London). He earned an intercalated BSc in Physiology (Hons., 1976), qualified in medicine (MB BS, 1979), and worked at the [[Royal Brompton Hospital]] and as medical registrar at [[Royal Postgraduate Medical School]] (Hammersmith Hospital).


==Career==
==Career==
;Immunological work
;Immunological work
Originally trained in lung mechanics, his PhD at the [[National Institute for Medical Research]] at Mill Hill, London was in T cell immunology. He has worked on protective and harmful immunological reactions to viruses, inflammatory lung disease and vaccine development since 1985, writing over 200 scientific articles ([[h-index]]= 78).
Originally trained in lung mechanics, his PhD at the [[National Institute for Medical Research]] at Mill Hill, London was in [[T cell]] immunology.<ref>{{Cite web |title=Future Virology Editorial Board |url=https://www.futuremedicine.com/journals/fvl/editors?publicationCode=fvl |access-date=2024-03-10 |website=Future Virology |language=en}}</ref> He has worked on protective and harmful immunological reactions to viruses, inflammatory lung disease and vaccine development since 1985, writing over 300 scientific articles ([[h-index]]= 101).<ref>{{Cite web |title=Peter Openshaw |url=https://scholar.google.com/citations?user=SzgPZAUAAAAJ&hl=en |access-date=2024-03-10 |website=scholar.google.com}}</ref> He was President of the [[British Society for Immunology]] between 2013 and 2018, the first clinician to hold the role. Openshaw was a member of the [[Academy of Medical Sciences (United Kingdom)|Academy of Medical Sciences]] and British Society for Immunology expert taskforce on [[COVID-19 pandemic|COVID-19]].<ref name=":0">{{Cite web |title=Peter Openshaw |url=https://www.imperial.ac.uk/people/p.openshaw |access-date=2024-03-10 |website=www.imperial.ac.uk}}</ref>


;Respiratory virus research
;Respiratory virus research
He was awarded the Chanock prize (2012, Santa Fe USA) in recognition of his lifetime achievement in work on [[respiratory syncytial virus]] (RSV) research. He has been involved in influenza policy since 2002 as a member of UK advisory boards and was Vice President of ESWI (European Scientific Working Group on Influenza) from 2009-2014. In 2009 he set up the MOSAIC consortium, a collaboration of 45 co-investigators studying the host response to influenza in patients admitted to 11 hospitals in London and Liverpool (Wellcome Trust/MRC support) and directs studies of viral challenge of human volunteers.
He was awarded the Chanock prize (2012, Santa Fe USA) in recognition of his lifetime achievement in work on [[respiratory syncytial virus]] (RSV) research. He has been involved in influenza policy since 2002 as a member of UK advisory boards and was Vice President of European Scientific Working Group on Influenza (ESWI) from 2009-2014. In 2009 he set up the MOSAIC consortium, a collaboration of 45 co-investigators studying the host response to influenza in patients admitted to 11 hospitals in London and Liverpool (Wellcome Trust/MRC support) and directs studies of viral challenge of human volunteers.

He was Theme Lead for the Respiratory Theme and later the Infection Theme of the NIHR Imperial Biomedical Research Centre. Currently he works as Head of the Respiratory Infections Section at the National Heart and Lung Institute, a department of [[Imperial College London]].<ref name=":0" />


;Academic leadership
;Academic leadership
Openshaw established the academic department of Respiratory Medicine on the St Mary’s Campus of [[Imperial College]] and created the Centre for Respiratory Infection (Wellcome Trust funded). He became President of the [[British Society for Immunology]] in 2014, the first clinician to lead the Society. He has sat on numerous governmental, grant awarding and international committees.
Openshaw established the academic department of Respiratory Medicine on the St Mary’s Campus of [[Imperial College]] and created the Centre for Respiratory Infection (Wellcome Trust funded). He has sat on numerous governmental, grant awarding and international committees.

He was elected an Imperial College Consul for the Faculty of Medicine in 2016, becoming Senior Consul in 2019<ref>{{Cite web |date=2019-05-30 |title=Professor Peter Openshaw elected as Senior Consul at Imperial |url=https://www.imperial.ac.uk/news/191369/professor-peter-openshaw-elected-senior-consul/ |access-date=2024-03-11 |website=Imperial News |language=en}}</ref> and then Proconsul.<ref>{{Cite web |title=Knighthoods for Chief Medical Officers in COVID Dominated New Year Honours |url=https://www.medscape.co.uk/viewarticle/knighthoods-chief-medical-officers-covid-dominated-new-year-2022a100000a |access-date=2024-03-11 |website=Medscape UK |language=en}}</ref> He co-chaired Imperial's Working Together Task Group in 2021.<ref>{{Cite web |title=Working Together Task Group |url=https://www.imperial.ac.uk/about/leadership-and-strategy/provost/working-together-task-group/ |access-date=2024-03-11 |website=Imperial College London |language=en-GB}}</ref>


;Advisory
;Advisory
Line 31: Line 37:


== Honours ==
== Honours ==
Fellow of the [[Royal College of Physicians]] (1994), Fellow of the [[Academy of Medical Sciences]] (1999); Fellow of the [[Society of Biology]] (2014); [[National Institute for Health Research]] (NIHR) Senior Investigator (2013).
Openshaw is a Fellow of the [[Royal College of Physicians]] (1994), a Fellow of the [[Academy of Medical Sciences]] (1999) and a Fellow of the [[Society of Biology]] (2014).<ref>{{Cite web |title=Honours and Memberships - Peter Openshaw - Professor of Experimental Medicine |url=https://www.imperial.ac.uk/people/p.openshaw/honours-and-memberships.html |access-date=2024-03-11 |website=www.imperial.ac.uk}}</ref> He was selected as Senior Investigator by [[National Institute for Health and Care Research|National Institute for Health Research]] (NIHR) in 2013 and 2020.<ref>{{Cite web |last=Openshaw |first=Peter |date=2017-10-04 |title=Vaccines are vital: there's never been a more exciting time to be a vaccinologist! |url=https://blogs.imperial.ac.uk/imperial-medicine/2017/10/04/vaccines-are-vital/ |access-date=2024-03-11 |website=Imperial Medicine Blog |language=en-GB}}</ref><ref>{{Cite web |title=NIHR Senior Investigator awards for Imperial |url=https://imperialbrc.nihr.ac.uk/2020/02/19/nihr-si/ |access-date=2024-03-11 |website=NIHR Imperial Biomedical Research Centre |language=en-GB}}</ref>


Openshaw was was appointed [[Commander of the Order of the British Empire]] (CBE) in the [[2022 New Year Honours]] for services to medicine and immunology.<ref>{{London Gazette|issue=63571|supp=y|page=N10|date=1 January 2022}}</ref>
Openshaw was appointed [[Commander of the Order of the British Empire]] (CBE) in the [[2022 New Year Honours]] for services to medicine and immunology.<ref>{{London Gazette|issue=63571|supp=y|page=N10|date=1 January 2022}}</ref>


== Selected publications ==
== Selected publications ==
*{{cite journal | last1 = Chiu | first1 = C | last2 = Openshaw | first2 = PJ | year = 2015 | title = Antiviral B cell and T cell immunity in the lungs | journal = Nature Immunology | volume = 16 | issue = 1| pages = 18–26 | doi = 10.1038/ni.3056 | pmid = 25521681 | pmc = 7097128 }}
*{{cite journal |last1=Hansel |first1=TT |last2=Johnston |first2=SL |last3=Openshaw |first3=PJ |year=2013 |title=Microbes and mucosal immune responses in asthma |doi=10.1016/S0140-6736(12)62202-8 |pmid=23428115 |journal=Lancet |volume=381 |issue=9869 |pages=861–873 |s2cid=24596808 |url=https://zenodo.org/record/3423604}}
*{{cite journal | last1 = Guvenel | first1 = AK | last2 = Chiu | first2 = C | last3 = Openshaw | first3 = PJ | year = 2014 | title = Current concepts and progress in RSV vaccine development | journal = Expert Rev Vaccines | volume = 13| issue = 3| pages = 333–44| pmid = 24405366 | doi=10.1586/14760584.2014.878653| s2cid = 22216901 }}
*{{cite journal |last1=Chiu |first1=C |last2=Openshaw |first2=PJ |year=2015 |title=Antiviral B cell and T cell immunity in the lungs |journal=Nature Immunology |volume=16 |issue=1 |pages=18–26 |doi=10.1038/ni.3056 |pmid=25521681 |pmc=7097128}}
*{{cite journal | last1 = Schnoeller | first1 = C | last2 = Roux | first2 = X | last3 = Sawant | first3 = D | last4 = Raze | first4 = D | last5 = Olszewska | first5 = W | last6 = Locht | first6 = C | last7 = Openshaw | first7 = PJ | year = 2013 | title = Attenuated Bordetella Pertussis Vaccine Protects against RSV Disease via an IL-17-dependent Mechanism | journal = Am J Respir Crit Care Med | volume = 189| issue = 2| pages = 194–202| doi = 10.1164/rccm.201307-1227OC | pmid = 24261996 | pmc = 3983892 }}
*{{Cite journal |last1=Habibi |first1=Maximillian S. |last2=Thwaites |first2=Ryan S. |last3=Openshaw |first3=Peter |last4=Jozwik |first4=Agnieszka |last5=Paras |first5=Allan |last6=Kirsebom |first6=Freja |last7=Varese |first7=Augusto |last8=Owen |first8=Amber |last9=Cuthbertson |first9=Leah |last10=James |first10=Phillip |last11=Tunstall |first11=Tanushree |last12=Nickle |first12=David |last13=Hansel |first13=Trevor T. |last14=Moffatt |first14=Miriam F. |last15=Johansson |first15=Cecilia |display-authors=3 |date=2020-10-09 |title=Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection |journal=Science |language=en |volume=370 |issue=6513 |doi=10.1126/science.aba9301 |issn=0036-8075 |pmc=7613218 |pmid=33033192}}
*{{Cite journal |last1=Thwaites |first1=Ryan S |last2=Sanchez Sevilla Uruchurtu |first2=Ashley |last3=Openshaw |first3=Peter |last4=Liew |first4=Felicity |last5=Russell |first5=Clark D |last6=Moore |first6=Shona C |last7=Fairfield |first7=Cameron |last8=Carter |first8=Edwin |last9=Abrams |first9=Simon |last10=Short |first10=Charlotte-Eve |last11=Thaventhiran |first11=Thilipan |last12=Bergstrom |first12=Emma |last13=Gardener |first13=Zoe |last14=Ascough |first14=Stephanie |last15=Chiu |first15=Christopher |display-authors=3 |date=2021-03-04 |title=Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19 |journal=Science Immunology |language=en |volume=6 |issue=57 |doi=10.1126/sciimmunol.abg9873 |pmid=33692097 |pmc=8128298 |issn=2470-9468}}
*{{cite journal | last1 = Loebbermann | first1 = J | last2 = Thornton | first2 = H | last3 = Johansson | first3 = C | last4 = Openshaw | first4 = PJM | year = 2013 | title = Defective immunoregulation in vaccine-augmented viral lung disease, restored by selective chemoattraction of regulatory T cells | journal = Proc Natl Acad Sci USA | volume = 110 | issue = 8| pages = 2987–2992 | doi = 10.1073/pnas.1217580110 | pmid=23382205 | pmc=3581918| url = http://spiral.imperial.ac.uk/bitstream/10044/1/19190/6/PNAS_110_8_2013.pdf | doi-access = free }}
*{{Cite journal |last=Openshaw |first=Peter J. M. |date=2022-01-07 |title=Using correlates to accelerate vaccinology |url=https://www.science.org/doi/10.1126/science.abn0007 |journal=Science |language=en |volume=375 |issue=6576 |pages=22–23 |doi=10.1126/science.abn0007 |pmid=34990231 |bibcode=2022Sci...375...22O |issn=0036-8075}}
*{{cite journal | last1 = Hansel | first1 = TT | last2 = Johnston | first2 = SL | last3 = Openshaw | first3 = PJ | year = 2013 | title = Microbes and mucosal immune responses in asthma | doi = 10.1016/S0140-6736(12)62202-8 | pmid = 23428115 | journal = Lancet | volume = 381 | issue = 9869| pages = 861–873 | s2cid = 24596808 | url = https://zenodo.org/record/3423604 }}
*{{cite journal | last1 = Everitt | first1 = AR | last2 = Clare | first2 = S | last3 = Pertel | first3 = T | last4 = John | first4 = SP | last5 = Wash | first5 = RS | last6 = Smith | first6 = SE | last7 = Chin | first7 = CR | last8 = Feeley | first8 = EM | last9 = Sims | first9 = JS | last10 = Adams | first10 = DJ | last11 = Wise | first11 = HM | last12 = Kane | first12 = L | last13 = Goulding | first13 = D | last14 = Digard | first14 = P | last15 = Anttila | first15 = V | last16 = Baillie | first16 = JK | last17 = Walsh | first17 = TS | last18 = Hume | first18 = DA | last19 = Palotie | first19 = A | last20 = Xue | first20 = Y | last21 = Colonna | first21 = V | last22 = Tyler-Smith | first22 = C | last23 = Dunning | first23 = J | last24 = Gordon | first24 = SB | last25 = Investigators | first25 = GenISIS | last26 = Mosaic Investigators | first26 = Smyth RL | last27 = Openshaw | first27 = PJ | last28 = Dougan | first28 = G | last29 = Brass | first29 = AL | last30 = Kellam | first30 = P | year = 2012 | title = IFITM3 restricts the morbidity and mortality associated with influenza | journal = Nature | volume = 484 | issue = 7395| pages = 519–23 | doi = 10.1038/nature10921 | pmid=22446628| pmc = 3648786 }}
*{{Cite journal |last1=Pairo-Castineira |first1=Erola |last2=Rawlik |first2=Konrad |last3=Openshaw |first3=Peter |last4=Qi |first4=Ting |last5=Wu |first5=Yang |last6=Nassiri |first6=Isar |last7=McConkey |first7=Glenn A. |last8=Zechner |first8=Marie |last9=Klaric |first9=Lucija |last10=Griffiths |first10=Fiona |last11=Oosthuyzen |first11=Wilna |last12=Kousathanas |first12=Athanasios |last13=Richmond |first13=Anne |last14=Millar |first14=Jonathan |last15=Russell |first15=Clark D. |display-authors=3 |date=2023-05-25 |title=GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 |journal=Nature |language=en |volume=617 |issue=7962 |pages=764–768 |doi=10.1038/s41586-023-06034-3 |issn=0028-0836 |pmc=10208981 |pmid=37198478}}
*{{cite journal | last1 = Loebbermann | first1 = J. | last2 = Thornton | first2 = H. | last3 = Durant | first3 = L. | last4 = Sparwasser | first4 = T. | last5 = Webster | first5 = K. E. | last6 = Sprent | first6 = J. | last7 = Culley | first7 = F.J. | last8 = Johansson | first8 = C. | last9 = Openshaw | first9 = P. | year = 2012 | title = Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection | journal = Mucosal Immunology | volume = 5| issue = 2| pages = 161–172| doi = 10.1038/mi.2011.62 | pmid = 22236998 | pmc = 3282434 }}
*{{Cite journal |last1=Thwaites |first1=Ryan S. |last2=Uruchurtu |first2=Ashley S. S. |last3=Openshaw |first3=Peter |last4=Cole |first4=Megan E. |last5=Singh |first5=Nehmat |last6=Poshai |first6=Nelisa |last7=Jackson |first7=David |last8=Hoschler |first8=Katja |last9=Baker |first9=Tina |last10=Scott |first10=Ian C. |last11=Ros |first11=Xavier Romero |last12=Cohen |first12=Emma Suzanne |last13=Zambon |first13=Maria |last14=Pollock |first14=Katrina M. |last15=Hansel |first15=Trevor T. |display-authors=3 |date=2023-12-05 |title=Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine |journal=Nature Communications |language=en |volume=14 |issue=1 |page=8053 |doi=10.1038/s41467-023-43842-7 |issn=2041-1723 |pmc=10697962 |pmid=38052824|bibcode=2023NatCo..14.8053T }}
*{{cite journal | last1 = Nguyen-Van-Tam | first1 = JS | last2 = Openshaw | first2 = PJM | last3 = Hashim | first3 = A | last4 = Gadd | first4 = EM | last5 = Lim | first5 = WS | last6 = Semple | first6 = MG | last7 = Read | first7 = RC | last8 = Taylor | first8 = BL | last9 = Brett | first9 = SJ | last10 = McMenamin | first10 = J | last11 = Enstone | first11 = JE | last12 = Armstrong | first12 = C | last13 = Nicholson | first13 = KG | year = 2010 | title = Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza | journal = Thorax | volume = 65 | issue = 7| pages = 645–51 | doi=10.1136/thx.2010.135210 | pmid=20627925 | pmc=2921287}}
*{{Cite journal |last1=Sidhu |first1=Jasmin K |last2=Siggins |first2=Matthew K |last3=Openshaw |first3=Peter J M |last4=Russell |first4=Clark D |last5=Uruchurtu |first5=Ashley S S |last6=Davis |first6=Christopher |last7=Turtle |first7=Lance |last8=Moore |first8=Shona C |last9=Hardwick |first9=Hayley E |last10=Oosthuyzen |first10=Wilna |last11=Thomson |first11=Emma C |last12=Semple |first12=Malcolm G |last13=Baillie |first13=J Kenneth |last14=Thwaites |first14=Ryan S |display-authors=3 |date=2023-12-22 |title=Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19 |url=https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiad590/7491611 |journal=The Journal of Infectious Diseases |language=en |doi=10.1093/infdis/jiad590 |pmid=38134401 |issn=0022-1899|hdl=20.500.11820/bed8141e-e4f2-482e-beae-1d084fe9ae37 |hdl-access=free }}
*{{Cite journal |last1=Wagstaffe |first1=Helen R. |last2=Thwaites |first2=Ryan S. |last3=Openshaw |first3=Peter |last4=Sidhu |first4=Jasmin K. |last5=McKendry |first5=Richard |last6=Ascough |first6=Stephanie |last7=Papargyris |first7=Loukas |last8=Collins |first8=Ashley M. |last9=Xu |first9=Jiayun |last10=Lemm |first10=Nana-Marie |last11=Siggins |first11=Matthew K. |last12=Chain |first12=Benny M. |last13=Killingley |first13=Ben |last14=Kalinova |first14=Mariya |last15=Mann |first15=Alex |display-authors=3 |date=2024-09-02 |title=Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults |url=https://www.science.org/doi/10.1126/sciimmunol.adj9285 |journal=Science Immunology |language=en |volume=9 |issue=92 |pages=eadj9285 |doi=10.1126/sciimmunol.adj9285 |pmid=38335268 |issn=2470-9468}}
*{{cite journal | last1 = Moghaddam | first1 = A | last2 = Olszewska | first2 = W | last3 = Wang | first3 = B | last4 = Tregoning | first4 = JS | last5 = Helson | first5 = R | last6 = Sattentau | first6 = QJ | last7 = Openshaw | first7 = PJM | year = 2006 | title = A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines | journal = Nat. Med. | volume = 12 | issue = 8| pages = 905–907 | doi=10.1038/nm1456| pmid = 16862151 | hdl = 10044/1/21962 | s2cid = 24601291 | hdl-access = free }}


==References==
==References==
Line 54: Line 60:
[[Category:1954 births]]
[[Category:1954 births]]
[[Category:Living people]]
[[Category:Living people]]
[[Category:People educated at Millfield]]
[[Category:People educated at Sidcot School]]
[[Category:People educated at Sidcot School]]
[[Category:People educated at Bootham School]]
[[Category:People educated at Bootham School]]

Latest revision as of 04:01, 7 December 2024

Peter Openshaw
CBE, FRCP, FMedSci
Born (1954-11-11) 11 November 1954 (age 70)
Glastonbury, Somerset, England
Alma materGuy's Hospital
Spouse
​
(date missing)​
Scientific career
FieldsImmunology
InstitutionsImperial College London
ThesisBenefit and harm from immunity to respiratory syncytial virus (1988)

Peter John Morland Openshaw, CBE, FRCP, FMedSci (born 11 November 1954) is a British clinician and scientist specialising in lung immunology, particularly defence against viral infections. He trained in lung diseases and undertook a PhD in immunology before establishing a laboratory at St Mary's Hospital Medical School (later part of Imperial College London). He created the academic department of Respiratory Medicine and the Centre for Respiratory Infection at Imperial College and was elected President of the British Society for Immunology in 2014.

Early life

[edit]

Openshaw was born in 1954 in Glastonbury, Somerset. He attended Millfield Junior School, then the Quaker boarding schools Sidcot School and Bootham School, followed by Guy's Hospital Medical School (University of London). He earned an intercalated BSc in Physiology (Hons., 1976), qualified in medicine (MB BS, 1979), and worked at the Royal Brompton Hospital and as medical registrar at Royal Postgraduate Medical School (Hammersmith Hospital).

Career

[edit]
Immunological work

Originally trained in lung mechanics, his PhD at the National Institute for Medical Research at Mill Hill, London was in T cell immunology.[1] He has worked on protective and harmful immunological reactions to viruses, inflammatory lung disease and vaccine development since 1985, writing over 300 scientific articles (h-index= 101).[2] He was President of the British Society for Immunology between 2013 and 2018, the first clinician to hold the role. Openshaw was a member of the Academy of Medical Sciences and British Society for Immunology expert taskforce on COVID-19.[3]

Respiratory virus research

He was awarded the Chanock prize (2012, Santa Fe USA) in recognition of his lifetime achievement in work on respiratory syncytial virus (RSV) research. He has been involved in influenza policy since 2002 as a member of UK advisory boards and was Vice President of European Scientific Working Group on Influenza (ESWI) from 2009-2014. In 2009 he set up the MOSAIC consortium, a collaboration of 45 co-investigators studying the host response to influenza in patients admitted to 11 hospitals in London and Liverpool (Wellcome Trust/MRC support) and directs studies of viral challenge of human volunteers.

He was Theme Lead for the Respiratory Theme and later the Infection Theme of the NIHR Imperial Biomedical Research Centre. Currently he works as Head of the Respiratory Infections Section at the National Heart and Lung Institute, a department of Imperial College London.[3]

Academic leadership

Openshaw established the academic department of Respiratory Medicine on the St Mary’s Campus of Imperial College and created the Centre for Respiratory Infection (Wellcome Trust funded). He has sat on numerous governmental, grant awarding and international committees.

He was elected an Imperial College Consul for the Faculty of Medicine in 2016, becoming Senior Consul in 2019[4] and then Proconsul.[5] He co-chaired Imperial's Working Together Task Group in 2021.[6]

Advisory

Openshaw is a member of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) in the UK.[7]

Honours

[edit]

Openshaw is a Fellow of the Royal College of Physicians (1994), a Fellow of the Academy of Medical Sciences (1999) and a Fellow of the Society of Biology (2014).[8] He was selected as Senior Investigator by National Institute for Health Research (NIHR) in 2013 and 2020.[9][10]

Openshaw was appointed Commander of the Order of the British Empire (CBE) in the 2022 New Year Honours for services to medicine and immunology.[11]

Selected publications

[edit]

References

[edit]
  1. ^ "Future Virology Editorial Board". Future Virology. Retrieved 10 March 2024.
  2. ^ "Peter Openshaw". scholar.google.com. Retrieved 10 March 2024.
  3. ^ a b "Peter Openshaw". www.imperial.ac.uk. Retrieved 10 March 2024.
  4. ^ "Professor Peter Openshaw elected as Senior Consul at Imperial". Imperial News. 30 May 2019. Retrieved 11 March 2024.
  5. ^ "Knighthoods for Chief Medical Officers in COVID Dominated New Year Honours". Medscape UK. Retrieved 11 March 2024.
  6. ^ "Working Together Task Group". Imperial College London. Retrieved 11 March 2024.
  7. ^ "New and Emerging Respiratory Virus Threats Advisory Group". GOV.UK. Retrieved 20 March 2020.
  8. ^ "Honours and Memberships - Peter Openshaw - Professor of Experimental Medicine". www.imperial.ac.uk. Retrieved 11 March 2024.
  9. ^ Openshaw, Peter (4 October 2017). "Vaccines are vital: there's never been a more exciting time to be a vaccinologist!". Imperial Medicine Blog. Retrieved 11 March 2024.
  10. ^ "NIHR Senior Investigator awards for Imperial". NIHR Imperial Biomedical Research Centre. Retrieved 11 March 2024.
  11. ^ "No. 63571". The London Gazette (Supplement). 1 January 2022. p. N10.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Peter_Openshaw_(immunologist)&oldid=1261640260"